Jennifer H Benbow1, April D Elam1,2, Krista L Bossi2, Danae L Massengill1,2, Elizabeth Brandon-Warner1, William E Anderson3, Catherine R Culberson1, Mark W Russo2, Andrew S deLemos2, Laura W Schrum4. 1. Liver Pathobiology Laboratory, Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC, 28203, USA. 2. Center for Liver Diseases and Liver Transplant, Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC, 28203, USA. 3. Center for Outcomes Research and Evaluation, Carolinas Medical Center, Charlotte, NC, 28203, USA. 4. Liver Pathobiology Laboratory, Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC, 28203, USA. laura.schrum@carolinashealthcare.org.
Abstract
BACKGROUND AND AIM: Hepatitis C virus (HCV)-related cirrhosis, one of the most common etiologies of liver cirrhosis in the Western world, is a risk factor for hepatocellular carcinoma. To confirm and improve current effectiveness of screening and prognosis of patients with established cirrhosis, a credible, simple plasma biomarker is needed. Hepatic stellate cell activation, a pivotal event in cirrhosis development, results in increased secretion of extracellular matrix proteins, including tenascin-C (TnC). Herein, we tested TnC as a simple biomarker to identify cirrhotic patients with active HCV infection from those with HCV eradication. METHODS: A prospective study of subjects with HCV-related cirrhosis, stratified into two groups, HCV or virologic cure, was conducted. Plasma TnC expression was measured by ELISA and Western blots. TnC values were correlated with markers of liver injury and ROC analyses performed between groups. RESULTS: The HCV cirrhotic cohort, consisting mostly of men (56%), Caucasians (76%), and genotype 1a or 1b (84%), was compared to healthy controls (HCs). Plasma TnC was significantly higher in HCV cirrhotic patients with active infection compared to HCs (P < 0.0001) and virologic cure (P < 0.0001). TnC concentrations in virologic cure subjects were not statistically different from HCs. TnC levels correlated with AST, platelets, MELD, APRI, FIB-4, and Child-Pugh score. TnC and AST together were significantly better indicators of cirrhosis in patients with active HCV infection than other markers tested. CONCLUSIONS: TnC and AST provided the best model for discriminating HCV cirrhotics with active infection from HC and virologic cure cohorts over current liver injury markers, suggesting TnC as a potential indicator of ongoing hepatic injury and inflammation.
BACKGROUND AND AIM: Hepatitis C virus (HCV)-related cirrhosis, one of the most common etiologies of liver cirrhosis in the Western world, is a risk factor for hepatocellular carcinoma. To confirm and improve current effectiveness of screening and prognosis of patients with established cirrhosis, a credible, simple plasma biomarker is needed. Hepatic stellate cell activation, a pivotal event in cirrhosis development, results in increased secretion of extracellular matrix proteins, including tenascin-C (TnC). Herein, we tested TnC as a simple biomarker to identify cirrhotic patients with active HCV infection from those with HCV eradication. METHODS: A prospective study of subjects with HCV-related cirrhosis, stratified into two groups, HCV or virologic cure, was conducted. Plasma TnC expression was measured by ELISA and Western blots. TnC values were correlated with markers of liver injury and ROC analyses performed between groups. RESULTS: The HCV cirrhotic cohort, consisting mostly of men (56%), Caucasians (76%), and genotype 1a or 1b (84%), was compared to healthy controls (HCs). Plasma TnC was significantly higher in HCV cirrhoticpatients with active infection compared to HCs (P < 0.0001) and virologic cure (P < 0.0001). TnC concentrations in virologic cure subjects were not statistically different from HCs. TnC levels correlated with AST, platelets, MELD, APRI, FIB-4, and Child-Pugh score. TnC and AST together were significantly better indicators of cirrhosis in patients with active HCV infection than other markers tested. CONCLUSIONS:TnC and AST provided the best model for discriminating HCV cirrhotics with active infection from HC and virologic cure cohorts over current liver injury markers, suggesting TnC as a potential indicator of ongoing hepatic injury and inflammation.
Entities:
Keywords:
Biomarker; Cirrhosis/cirrhotics; Fibrosis; Hepatitis C virus; Tenascin-C
Authors: Andreas Glässner; Marianne Eisenhardt; Benjamin Krämer; Christian Körner; Martin Coenen; Tilman Sauerbruch; Ulrich Spengler; Jacob Nattermann Journal: Lab Invest Date: 2012-03-26 Impact factor: 5.662
Authors: Gwon-Soo Jung; Jae-Han Jeon; Yeon-Kyung Choi; Se Young Jang; Soo Young Park; Mi-Kyung Kim; Eui-Cheol Shin; Won-Il Jeong; In-Kyu Lee; Yu Na Kang; Keun-Gyu Park Journal: Liver Int Date: 2015-06-03 Impact factor: 5.828
Authors: Mattias Mandorfer; Karin Kozbial; Philipp Schwabl; Clarissa Freissmuth; Rémy Schwarzer; Rafael Stern; David Chromy; Albert Friedrich Stättermayer; Thomas Reiberger; Sandra Beinhardt; Wolfgang Sieghart; Michael Trauner; Harald Hofer; Arnulf Ferlitsch; Peter Ferenci; Markus Peck-Radosavljevic Journal: J Hepatol Date: 2016-05-27 Impact factor: 25.083
Authors: M Yano; H Kumada; M Kage; K Ikeda; K Shimamatsu; O Inoue; E Hashimoto; J H Lefkowitch; J Ludwig; K Okuda Journal: Hepatology Date: 1996-06 Impact factor: 17.425
Authors: Ali A Mokdad; Alan D Lopez; Saied Shahraz; Rafael Lozano; Ali H Mokdad; Jeff Stanaway; Christopher J L Murray; Mohsen Naghavi Journal: BMC Med Date: 2014-09-18 Impact factor: 8.775
Authors: Akif Altinbas; Jacinta A Holmes; Shadi Salloum; Anna Lidofsky; Nadia Alatrakchi; Ma Somsouk; Peter Hunt; Steven Deeks; Kara W Chew; Georg Lauer; Annie Kruger; Wenyu Lin; Raymond T Chung Journal: Biomark Med Date: 2022-07-05 Impact factor: 2.498